Cenicriviroc for the treatment of hiv-2 infection

MA39991AUndetermined Publication Date: 2015-12-10TOBIRA THERAPEUTICS INC

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: MA39991
Authority / Receiving Office: MA · MA
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2014-06-02
Filing Date: 2015-06-02
Publication Date: 2015-12-10

Application Information

Patent Timeline

02 Jun 2014

Priority

02 Jun 2015

Application

MA39991

10 Dec 2015

Publication

MA39991A

IPC: A61K31/4196; A61K31/5513; C07D403/14

CPC: A61K31/46; A61K31/513; A61K31/55; A61K9/2013; A61K9/2077; A61K31/4748; A61K31/4178; A61P31/18

Inventors: LEFEBVRE Eric

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

Cenicriviroc (cvc) is an orally active antagonist of ligand binding to c-c chemokine receptor type 5 (ccr5) and c-c chemokine receptor type 2 (ccr2). Cvc blocks the binding of rantes, mip-1α, and mip-1β to ccr5, and of mcp-1 / ccl2 to ccr2. Methods of treating hiv-2 infection and related conditions comprising administration of cvc are provided herein.

Need to check novelty before this filing date? Find Prior Art